ONBOARD AND UNDER YOUR CONTROL

DEXTENZA is an advancement in steroid treatment

  • Resorbable, so no need for removal1
    • Insert can be removed via saline irrigation or manual expression, if necessary1
  • Physicians rated DEXTENZA as easy to insert2,3*
  • Designed to deliver a tapered dose4
  • Contains fluorescein for visualization1
  • No additional components or assembly required1

*73.6% of physicians in Study 1, 76.4% in Study 2 and 79.6% in Study 3 rated DEXTENZA as easy to insert.

Over the course of 30 days post-op…

Built-in compliance with

To view the Phase 3 clinical program publications click here

Consider the preservative load

Preservatives (e.g., benzalkonium chloride) in some topical drops can cause changes in the ocular surface, which may lead to inflammation and damage to the tear film.6

DEXTENZA is
preservative-free1

ONBOARD USING A NOVEL TECHNOLOGY

DEXTENZA is dexamethasone delivered via hydrogel technology1,2

Activates1,2

  • With moisture and swells to fit securely in the canaliculus

Releases1,2

  • Dexamethasone for up to 30 days

Resorbs1,2

  • Slowly through the course of treatment and clears via the nasolacrimal duct

DEXTENZA is designed to:

  • Allow for physician-controlled administration4
  • Provide sustained coverage for up to 30 days1

Positive Patient Experience

Patients reported highly favorable outcomes in comfort, convenience, and satisfaction7

Survey results based on the responses from 201 DEXTENZA patients who participated in the most recent Phase 3 study7*

Study Limitations8

  • Qualitative written survey (questions not validated)
  • Relied on recall in an elderly population

*Intent-to-treat population.

References: 1. DEXTENZA [package insert). Bedford. MA: Ocular Therapeutlx, Inc: 2019. 2. Walters T et al. J Clin Exp Ophthalmol. 2016;7(4): 1-11. 3. Tyson S. et al. J Cataract Refract Surg 2019; 45:204–212. 4. Sawhney AS, Jarrett P, Bassett M, Blizzard C, inventors; Incept, LLC, assignee. Drug delivery through hydrogel plugs. US patent 8,409,606 B2. April 2, 2013. 5. Data on file 00663. Ocular Therapeutix Inc. 6. Baudouin C et al. Prog Retin Eye Res. 2010;29(4):312-334. 7. Data on file 00837. Ocular Therapeutix Inc. 8. Noecker RJ et al. Evaluating the Physician and Patient Experience of a Dexamethasone Insert (0.4 mg) in Patients Having Cataract Surgery. Presented at: American Society of Cataract and Refractive Surgery Annual Meeting. April 16, 2018; Washington, DC.

  open
  close
Full Prescribing Information
INDICATION

DEXTENZA is a corticosteroid indicated for the treatment of ocular inflammation and pain following ophthalmic surgery.

IMPORTANT SAFETY INFORMATION

Contraindications
DEXTENZA is contraindicated in patients with active corneal, conjunctival or canalicular infections, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella; mycobacterial infections; fungal diseases of the eye, and dacryocystitis.

Warnings and Precautions
Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. Intraocular pressure should be monitored during treatment.

Corticosteroids may suppress the host response and thus increase the hazard for secondary ocular infections. In acute purulent conditions, steroids may mask infection and enhance existing infection.

Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).

Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal culture should be taken when appropriate.

Use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.

Adverse Reactions
The most common ocular adverse reactions that occurred in patients treated with DEXTENZA were: anterior chamber inflammation including iritis and iridocyclitis (10%); intraocular pressure increased (6%); visual acuity reduced (2%); cystoid macular edema (1%); corneal edema (1%); eye pain (1%) and conjunctival hyperemia (1%).

The most common non-ocular adverse reaction that occurred in patients treated with DEXTENZA was headache (1%).

Please see Full Prescribing Information.